Table 1.
Main Baseline Characteristics of the Latin American REACH Cohort (n = 1816)a
| Baseline Characteristics | Asymptomatic Patients With Multiple Risk Factors [n = 234] | Patients With Established Vascular Disease | ||
|---|---|---|---|---|
| CAD [n = 1041] | CVD [n = 582] | PAD [n = 213] | ||
| Men, % | 41.0 | 72.3 | 56.7 | 63.4 |
| Age, mean (SD), y | 66.0 (10.3) | 66.2 (9.9) | 69.0 (10.2) | 69.1 (10.5) |
| DM, % | 80.8 | 37.2 | 37.5 | 56.8 |
| Hypertension, % | 89.7 | 75.3 | 77.7 | 81.7 |
| CHF, % | 4.7 | 11.0 | 6.9 | 6.6 |
| Hypercholesterolemia, % | 73.9 | 69.2 | 48.5 | 51.2 |
| BMI ≥30, % | 38.5 | 22.1 | 22.3 | 14.6 |
| WHtR ≥0.60, % | 65.0 | 42.7 | 45.0 | 34.7 |
| AF, % | 3.4 | 6.9 | 9.6 | 4.4 |
| Past or current smoking status, % | 37.2 | 57.0 | 43.3 | 65.6 |
| Current smoking status, % | 14.6 | 7.6 | 7.1 | 16.0 |
| ABI <0.9, % | 6.5% | 12.6 | 12.4 | 87.0 |
| Statin therapy, % | 67.9 | 75.0 | 47.8 | 46.9 |
| Aspirin therapy, % | 62.0 | 87.0 | 67.5 | 77.0 |
| Other antiplatelet therapy, % | 9.9 | 30.6 | 38.4 | 32.9 |
| Oral anticoagulant therapy, % | 1.7 | 6.4 | 14.4 | 10.0 |
| Diuretic therapy, % | 50.0 | 34.9 | 35.3 | 40.6 |
| ACEI therapy, % | 47.0 | 45.7 | 39.2 | 34.8 |
| ARB therapy, % | 29.7 | 20.2 | 20.6 | 21.4 |
| Insulin therapy, % | 18.1 | 9.8 | 9.0 | 23.5 |
Abbreviations: ABI, ankle/brachial index; ACEI, angiotensin‐converting enzyme inhibitor; AF, atrial fibrillation; ARB, angiotensin II receptor blocker; BMI, body mass index; CAD, coronary artery disease; CHF, congestive heart failure; CVD, cerebrovascular disease; DM, diabetes mellitus; PAD, peripheral artery disease; SD, standard deviation; WHtR, waist‐to‐height ratio.
a
Patients may not add up to 1816 because some individuals with established vascular disease have ≥1 identified vasculopathy location.